Therapy Areas: Hereditary Disorders
Kewalramani Appointed as New CEO at Vertex. Leiden to Transition to Role of Executive Chairman
26 July 2019 - - US-based biotechnology company Vertex Pharmaceuticals Inc.'s (NASDAQ: VRTX) board of directors has approved the planned transition of chairman, president and chief executive officer Jeffrey Leiden, M.D., Ph.D, into the role of executive chairman of the board, effective April 1, 2020, the company said.
At that time, Vertex's Chief Medical officer Reshma Kewalramani, M.D., will become president and chief executive officer and will be appointed to serve on the company's board of directors.
Kewalramani joined Vertex in February 2017 and currently serves as the company's executive vice president, global medicines development and medical affairs, and chief medical officer.
In this role, she oversees clinical development, medical affairs, drug safety and other related functions, and is responsible for developing, advising and driving execution of Vertex's clinical development programs.
Prior to Vertex, Dr. Kewalramani spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as vice president, Global Clinical Development, Nephrology and Metabolic Therapeutic Area and vice president, US Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules across six therapeutic areas.
Kewalramani completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women's Hospital combined program.
She received her medical degree, with honors, from the Boston University School of Medicine.
Kewalramani also completed the General Management Program at Harvard Business School and is an alumnus of the school. She is the industry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee.
Leiden has agreed to serve as executive chairman through 1Q23.
Vertex is a biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
The company has three approved medicines that treat the underlying cause of cystic fibrosis a rare, life-threatening genetic disease, and has several ongoing clinical and research programs in CF.
Beyond CF, Vertex has a pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney disease.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK.
Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America.